^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2 stimulant

    Related drugs:
    9d
    19-C-0017: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (clinicaltrials.gov)
    P1/2, N=5, Completed, National Cancer Institute (NCI) | N=70 --> 5 | Recruiting --> Completed
    Trial completion • Enrollment change • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL
    14d
    TILT-T776: A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy (2024-518088-37-01)
    P1, N=9, Completed, TILT Biotherapeutics Oy | Active, not recruiting --> Completed
    Trial completion
    |
    Bavencio (avelumab) • igrelimogene litadenorepvec (TILT-123)
    16d
    An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=78, Recruiting, Yonsei University
    New P2 trial
    |
    axitinib • SLC-3010
    23d
    TUNIMO: TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (clinicaltrials.gov)
    P1, N=32, Completed, TILT Biotherapeutics Ltd. | Recruiting --> Completed | N=18 --> 32 | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    igrelimogene litadenorepvec (TILT-123)
    24d
    TUNINTIL-2: TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • igrelimogene litadenorepvec (TILT-123)
    25d
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    25d
    Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov)
    P3, N=1449, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    27d
    RIOT 4B: Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    New P1 trial • First-in-human
    |
    Proleukin (aldesleukin)
    1m
    Bioinformatics Identification and Functional Analysis of Key Genes of Nucleotide Metabolism in Oral Squamous Cell Carcinoma. (PubMed, Oral Health Prev Dent)
    ADA, NT5E and TYMS can serve as potential diagnostic markers and therapeutic targets for OSCC. The study has reference value for early diagnosis and the development of individualised treatment strategies.
    Journal
    |
    CD73 (5'-Nucleotidase Ecto) • TYMS (Thymidylate Synthetase) • NT5E (5'-Nucleotidase Ecto) • MIR192 (MicroRNA 192) • MIR30B (MicroRNA 30b) • MIR215 (MicroRNA 215) • MIR30A (MicroRNA 30a)
    |
    Ontak (denileukin diftitox) • Zanosar (streptozocin) • Mustargen (mechlorethamine)
    1m
    A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD (clinicaltrials.gov)
    P2, N=25, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    IL2 (Interleukin 2)
    |
    Proleukin (aldesleukin)
    1m
    A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study (2025-522427-10-00)
    P1/2, N=10, Not yet recruiting, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
    New P1/2 trial
    |
    LDH elevation
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    1m
    APHP230867: Use of low doses of interleukin-2 in autism spectrum disorders (2025-522841-23-00)
    P1/2, N=22, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P1/2 trial